Compare TRNR & PRFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRNR | PRFX |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8M | 3.1M |
| IPO Year | 2023 | 2020 |
| Metric | TRNR | PRFX |
|---|---|---|
| Price | $1.76 | $0.75 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 31.7K | ★ 34.3K |
| Earning Date | 11-16-2026 | 09-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,530,000.00 | N/A |
| Revenue This Year | $117.64 | N/A |
| Revenue Next Year | $10.59 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 114.31 | N/A |
| 52 Week Low | $1.70 | $0.58 |
| 52 Week High | $3,378.70 | $5.39 |
| Indicator | TRNR | PRFX |
|---|---|---|
| Relative Strength Index (RSI) | 24.04 | 36.52 |
| Support Level | N/A | $0.58 |
| Resistance Level | $3.23 | $1.28 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.23 | -0.01 |
| Stochastic Oscillator | 14.08 | 30.52 |
Interactive Strength Inc provides an integrated home fitness platform that allows its customers to participate in interactive wellness and strength-based training sessions. Its health coaching services encompass guidance and coaching on nutrition, recovery, sleep, and other health and lifestyle categories. The company generates revenue from sales of its connected fitness products, membership revenue, and personal training revenue.
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.